Parasitic Infestations Therapeutics
1. Natroba patent expiration
Treatment: Topical treatment of head lice infestation in patients four (4) years of age and older; The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7030095 | CIPHER | Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs |
Jul, 2021
(4 years ago) | |
| US6063771 | CIPHER | Formulations for controlling human lice |
Jun, 2019
(6 years ago) | |
| US5496931 | CIPHER | Insecticide and miticide A83543 compounds and their method of production by fermentation |
Mar, 2013
(12 years ago) | |
| US6342482 | CIPHER | Formulations for controlling human lice |
Jun, 2019
(6 years ago) | |
| US9895388 | CIPHER | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2016 |
| M(M-152) | Nov 30, 2017 |
| New Indication(I-858) | Apr 28, 2024 |
Drugs and Companies using SPINOSAD ingredient
NCE-1 date: 18 January, 2015
Market Authorisation Date: 18 January, 2011
Dosage: SUSPENSION
More Information on Dosage
NATROBA family patents
2. Ulesfia patent expiration
Treatment: Topical treatment of lice infestations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5858383 | SHIONOGI INC | Methods and compositions for topical treatment of ectoparasites |
Aug, 2017
(8 years ago) | |
| US6139859 | SHIONOGI INC | Methods and compositions for topical treatment of ectoparasites |
Aug, 2017
(8 years ago) | |
| US6793931 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their applications |
Jul, 2022
(3 years ago) | |
| US7294342 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their application |
May, 2024
(1 year, 7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 09, 2014 |
Drugs and Companies using BENZYL ALCOHOL ingredient
NCE-1 date: 09 April, 2013
Market Authorisation Date: 09 April, 2009
Dosage: LOTION
How can I launch a generic of ULESFIA before it's drug patent expiration?
More Information on Dosage
ULESFIA family patents
3. Xdemvy patent
expiration
Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383659 | TARSUS | Isoxazoline derivatives as pesticides |
Jan, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690827 | TARSUS | Methods for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(12 years from now) | |
| US11690826 | TARSUS | Methods for treating demodex blepharitis using lotilaner formulations |
Dec, 2038
(12 years from now) | |
| US11197847 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(12 years from now) | |
| US10835517 | TARSUS | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
Dec, 2038
(12 years from now) | |
| US12171750 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(12 years from now) | |
| US11752137 | TARSUS | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(12 years from now) | |
| US12213964 | TARSUS | Isoxazoline parasiticide formulations |
Dec, 2038
(12 years from now) | |
| US12364685 | TARSUS | NA |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
4. Xeglyze patent expiration
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(8 years from now) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 5 months ago) | |
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents